BioPharmSignal logoBioPharmSignal

Biotech News

Fulgent Reports Third Quarter 2025 Financial Results

Fulgent Genetics, Inc. (FLGT)Fulgent Genetics, Inc.2026-06-25 13:46 ESTEarnings

Revenue of $84.1 million , growing 17% year-over-year Raising Full Year 2025 Revenue Guidance to $325.0 million Raising Full Year 2025 EPS Guidance to GAAP loss of approximately ( $1.70 ) per share and Non-GAAP income of $0.30 per share GAAP gross profit of $35.5 million , or GAAP gross margin of

Open original release

Related news

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Presents Updated FID-007 Data at ASCO 2026

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent to Participate in Upcoming Conferences

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Reports First Quarter 2026 Financial Results

View all latest news

Fulgent Genetics, Inc.

Fulgent Genetics is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

FLGTFulgent Genetics, Inc.2026-06-26 10:08 EST

Fulgent Presents Updated FID-007 Data at ASCO 2026

FLGTFulgent Genetics, Inc.2026-06-26 10:08 EST

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

FLGTFulgent Genetics, Inc.2026-06-26 10:08 EST

Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference

FLGTFulgent Genetics, Inc.2026-06-26 10:08 EST

Fulgent Reports Third Quarter 2025 Financial Results

FLGTFulgent Genetics, Inc.2026-06-26 10:08 EST

Fulgent to Participate in Upcoming Conferences

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States